Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases

Journal of Clinical Oncology

Volumn 19, Issue 7, 2001, Pages 2074-2083

  Carde, P ^a   Timmerman, R ^a   Mehta, M P ^a   Koprowski, C D ^a   Ford, J ^a   Tishler, R B ^a   Miles, D ^a   Miller, R A ^a   Renschler, M F ^a  

^a PHARMACYCLICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM TEXAPHYRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOACCUMULATION; BRAIN METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TUMOR LEVEL; FEMALE; HUMAN; LIVER TOXICITY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0035300617     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.7.2074     Document Type: Article

References (44)

1. Intracranial metastases from systemic cancer
2. Identification of prognostic factors in patients with brain metastases: A review of 1292 patients
3. Prognostic factors in brain metastases: Should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?
4. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials
5. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group
6. Prognostic factors in patients with brain metastases from lung carcinoma
7. Radiation therapy for brain metastases from lung carcinoma: Prospective randomized trial according to the level of lactate dehydrogenase
8. Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases
9. The palliation of brain metastases in a favorable patient population: A randomized clinical trial by the Radiation Therapy Oncology Group
10. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the Radiation Therapy Oncology Group (RTOG) 9104
11. The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group
12. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis
13. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age
14. A randomized trial of surgery in the treatment of single metastases to the brain
15. A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis
16. Stereotactic radio-surgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases
17. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung: Preliminary report by the Radiation Therapy Oncology Group
18. Chemical modifiers of radiation
19. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme
20. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916)
21. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: Report of RTOG trial 89-05
22. Gadolinium(III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI
23. One-electron reduction and oxidation studies of the radiation sensitizer gadolinium (III) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins
24. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer
25. Preclinical evaluation of gadolinium (III) texaphyrin complex: A new paramagnetic contrast agent for magnetic resonance imaging
26. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging
27. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases
28. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent
29. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity
30. 2+, Xcytrin)
31. 31P NMR studies of the effect of a redox cycling radiation sensitizer on tumor metabolism
32. The measurement of bioreductive capacity of tumor cells using methylene blue
33. Nonparametric estimation from incomplete observations
34. Sensitivity to chemical oxidants and radiation in CHO cell lines deficient irs oxidative pentose cycle activity
35. The importance of peroxide and superoxide in the X-ray response
36. Role of glutathione in the aerobic radiation response
37. Oxidation of cellular thiols by hydroxyethyldisulphide inhibits DNA double-strand-break rejoining in G6PD deficient mammalian cells
38. Glutathione export by human lymphoid cells: Depletion of glutathione by inhibition of its synthesis decreases export and increases sensitivity to irradiation
39. Mammalian cell studies with diamide
40. Diamide: Mechanisms of action and interactions with other sensitizers
41. Subcellular distribution of the radiation enhancer, motexafin gadolinium (Gd-Tex) using multi-pixel fluorescence microscopy in two cancer cell lines
42. Combined effects of angiostatin and ionizing radiation in antitumour therapy
43. Cell-cycle arrest versus cell death in cancer therapy
44. Relation between local result and total dose of radiotherapy for brain metastases